Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Biosimilar.
•
2 recomendaciones•526 vistas
Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Biosimilar.
Recomendados
Más contenido relacionado
Más de Bill Smith
Más de Bill Smith (20)
Último
Último (20)
Zarxio: The FDA's CDER Proprietary Name Review of the First FDA Approved Biosimilar.
- 1. FDA’s Center for Drug Evaluation and Research Proprietary Name Review Brand Acumen. The Global Leader in Pharmaceutical Name Development and Submission Strategy